Baxdrostat (Baxfendy)
Treatment of hypertension in adults.
In 796 patients with uncontrolled or resistant hypertension, baxdrostat 1 mg or 2 mg added to background therapy lowered seated systolic BP at 12 weeks vs placebo (placebo-corrected −8.7 and −9.8 mm Hg). Potassium >6.0 mmol/L: 2.3% and 3.0% vs 0.4%. RCT · phase 3 · n = 796 · N Engl J Med · 2025
In 217 adults with resistant hypertension, baxdrostat 2 mg added to background therapy lowered 24 h ambulatory systolic BP by 14·0 mm Hg more than placebo at 12 weeks (n=184 analysed). Potassium >6 mmol/L occurred in 3% vs 0%. RCT · phase 3 · n = 217 · Lancet · 2026